CAT-2054: Phase IIa data

Top-line data from a double-blind, U.S. Phase IIa trial in 153 patients with hypercholesterolemia showed that oral CAT-2054 plus atorvastatin missed the primary endpoint

Read the full 243 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE